Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Preferred Shares (2025)

Heron Therapeutics' Preferred Shares history spans 1 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Preferred Shares changed N/A year-over-year to $1.0 million; the TTM value through Dec 2025 reached $1.0 million, changed N/A, while the annual FY2025 figure was $1.0 million, N/A changed from the prior year.
  • Preferred Shares reached $1.0 million in Q4 2025 per HRTX's latest filing, down from $7.9 million in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $7.9 million in Q3 2025 to a low of $1.0 million in Q4 2025.